Yellow Fever Vaccines

Staples, J. Erin; Monath, Thomas P.; Gershman, Mark D.; Barrett, Alan D.T.

doi:10.1016/b978-0-323-35761-6.00063-8

Cited by 29 publications

(41 citation statements)

References 650 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the United States, the incidence of YEL-AVD is 0.25-0.4/ 100,000 doses and in Brazil, 21 cases were reported from 2007 to 2012, at a rate of 0.04 cases per 100,000 administered doses. In 2009, during the vaccination campaign in the State of São Paulo, 0.31 cases per 100,000 doses applied were observed, and in Rio Grande do Sul, the frequency observed was 0.11 per 100,000 doses applied [16].…”

Section: Yellow Fever: Disease and Vaccinementioning

confidence: 99%

“…According to Staples et al (2017), at least 100 cases of YEL-AVD had been reported worldwide and none were reported after revaccination until February 2017. In the United States, the incidence of YEL-AVD is 0.25-0.4/ 100,000 doses and in Brazil, 21 cases were reported from 2007 to 2012, at a rate of 0.04 cases per 100,000 administered doses.…”

Section: Yellow Fever: Disease and Vaccinementioning

confidence: 99%

See 1 more Smart Citation

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

et al. 2019

View full text Add to dashboard Cite

Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the (Continued on next page)

show abstract

Section: Yellow Fever: Disease and Vaccinementioning

confidence: 99%

Section: Yellow Fever: Disease and Vaccinementioning

confidence: 99%

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The 176th viral passage was selected to make vaccine sub-strains 17D-204 and 17DD because it was less lethal when delivered intracerebrally than a 114th passage strain, the first strain to lose pathogenicity in mice. A third sub-strain, which is a derivative of 17D-204, the 17D-213 sub-strain, was produced in 1977 and is a reference stock maintained by WHO for new manufacturers or emergency production [43,85].…”

Section: Yellow Fever Vaccines and Production Capacitymentioning

confidence: 99%

“…Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) was first described in 2001, although cases as far back as the 1970s have been identified retrospectively [43]. While YEL-AVDs are rare events, the case fatality rate is >60%.…”

Section: Safety Profile Of Yellow Fever Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

et al. 2019

View full text Add to dashboard Cite

Yellow fever is a potentially fatal, mosquito-borne viral disease that appears to be experiencing a resurgence in endemic areas in Africa and South America and spreading to non-endemic areas despite an effective vaccine. This trend has increased the level of concern about the disease and the potential for importation to areas in Asia with ecological conditions that can sustain yellow fever virus transmission. In this article, we provide a broad overview of yellow fever burden of disease, natural history, treatment, vaccine, prevention and control initiatives, and vaccine and therapeutic agent development efforts.

show abstract

Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick‐borne encephalitis and dengue virus infections

Roßbacher,

Malafa,

Huber

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Arthropod‐borne flaviviruses include a number of medically relevant human pathogens such as the mosquito‐borne dengue (DEN), Zika, and yellow fever (YF) viruses as well as tick‐borne encephalitis virus (TBEV). All flaviviruses are antigenically related and anamnestic responses due to prior immunity can modulate antibody specificities in subsequent infections or vaccinations. In our study, we analyzed the induction of broadly flavivirus cross‐reactive antibodies in tick‐borne encephalitis (TBE) and DEN patients without or with prior flavivirus exposure through TBE and/or YF vaccination, and determined the contribution of these antibodies to TBE and dengue virus (DENV) neutralization. In addition, we investigated the formation of cross‐reactive antibodies in TBE‐vaccination breakthroughs (VBTs). A TBEV infection without prior YF or TBE vaccination induced predominantly type‐specific antibodies. In contrast, high levels of broadly cross‐reactive antibodies were found in samples from TBE patients prevaccinated against YF as well as in DEN patients prevaccinated against TBE and/or YF. While these cross‐reactive antibodies did not neutralize TBEV, they were effective in neutralizing DENV. This discrepancy points to structural differences between the two viruses and indicates that broadly cross‐reactive epitopes are less accessible in TBEV than in DENV. In TBE VBT infections, type‐specific antibodies dominated the antibody response, thus revealing no difference from that of unvaccinated TBE patients. Our results emphasize significant differences in the structural properties of different flaviviruses that have an impact on the induction of broadly cross‐reactive antibodies and their functional activities in virus neutralization.

show abstract

Yellow Fever Vaccines

Cited by 29 publications

References 650 publications

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick‐borne encephalitis and dengue virus infections

Contact Info

Product

Resources

About